Fresh Money: 2011 Q1

Old Beggar, 1916, by Louis Dewis, painted just...
Image via Wikipedia

According to the Boston Globe, the top New England venture-funded sector in Q1 2011 was medical devices and equipment, at $145 million.  That’s great news and a testament to the local medical device innovation economy.

On the other hand, life science venture capitalists in New England closed no new funds in Q1.   That’s not great news.  There has been some fund-raising activity, so we can hope for a better Q2.  In fact, Bessemer Ventures closed a $1.6B fund in early April, which will include medical devices as a target investment sector, so Q2 is off to a good start.

If you’re raising money, you should know which life science funds actually did raise money in Q1 2011.  How do you find out? Continue reading “Fresh Money: 2011 Q1”

Customer-Facing Metrics for Product Launch Assessment

Adoption Curves
Image by Nathan Laurell via Flickr

Medical device product development is justifiably hard. Innovative devices push technical and clinical boundaries. Before being used for patient care, new devices must undergo rigorous analysis and testing. It takes months or years to bring new medical devices from concept to reality. So it’s a big milestone when the last signatures finally authorize product release, and the first units ship to the first customers. Time to celebrate? Not so fast.

Your first customers decide if you should celebrate. Initial shipments are just steps towards the ultimate objective – satisfying unmet customer needs and building a great business. How well have you really done? A couple of weeks ago I wrote about the need for metrics to be customer-facing. Here are a few suggestions for quick-and-dirty customer-facing metrics to help you assess your product launch.

Continue reading “Customer-Facing Metrics for Product Launch Assessment”

Kickstart Your Social Media Strategy With a Blog

Typewriter adler3
Image via Wikipedia

My post on social media strategies for medical device companies remains near the top of my most-read list.  If you still haven’t gotten going, Mark Suster of GRP partners explains both why startups need to blog and how to get started.  Advice worth following.

Medical Device VC Funding: Slide Deck – Part 2 – Platforms

VisiCalc, the earliest generally agreed exampl...
Image via Wikipedia

Platform technologies have a certain allure. Look at MicroCHIPS, poised to revolutionize glucose monitoring and drug delivery (starting with osteoporosis, diabetes and cardiology drugs). Look at Seventh Sense Biosystems, hard at work developing rapid, simple-to-use diagnostics that measure “several classes of analytes including small molecules, peptides, proteins, and nucleic acids.” Medical device geeks like me can’t help being impressed.

Broadly defined, platform technologies are families of IP that enable multiple distinct clinical applications for distinct patient populations. MicroCHIPS and Seventh Sense are great examples.

Because platforms address multiple market opportunities, the revenue potential of a company with a platform technology can be several times that of a single application company. Does that mean platform technologies are easier to fund?

Pitching platform technologies to VC’s can be challenging. First, cool new technologies need lots of explanation. Second, presenting multiple market opportunities takes lots of time. One of my most popular posts has been “Medical Device VC Funding: Slide Deck – Part 1,” which covers a company developing a single medical device product to address a single unmet need. How should companies with platform technologies present to VC’s?

Continue reading “Medical Device VC Funding: Slide Deck – Part 2 – Platforms”

Competition On Multiple Fronts

Juarez, fortification of adobes during battle ...
Image by The Library of Congress via Flickr

Most trade disputes between medical device companies involve intellectual property (IP). While the conflict between LightLab and Volcano is relatively small compared to others in the medical device industry (e.g. check out last year’s $1.7B battle between Boston Scientific and J&J), the lessons to be learned are large.

Briefly, Volcano is developing a competing product to LightLab’s OCT system, and accelerated their program by purchasing LightLab’s laser supplier Axsun. The dispute involves allegations of patent infringement, unauthorized disclosure of confidential information, and contract performance issues.

At the end of January, both LightLab and Volcano issued press releases claiming victory in the most recent rulings. Eric Swanson, LightLab co-founder and editor of Optical Coherence Tomography News, just posted an entertaining summary of the recent court documents. Despite these rulings, the legal skirmishes will continue, and the only safe prediction is that the lawyers will be the winners.

What are the lessons learned?

Continue reading “Competition On Multiple Fronts”

Venture Capitalist Bloggers

Sand Hill Road Sign
Image by Mark Coggins via Flickr

You can’t be a credible social media venture capitalist if you’re not an active social media user.  Blogs and twitter are the social media of choice, and VC’s have created a lot of content worth reading.  On my blogroll I’ve included some of my favorites, but now you can find the comprehensive list of all VC blogs at the Venture Capital (VC) Blog Directory – 2011 Edition, put together by Larry Cheng of Volition Capital.  Thanks to Ty Danco for pointing it out.

Note that only a handful of life science VC’s have blogs.  Savvy tech VC’s have figured out that blogging and tweeting can help build their VC (and personal) brand, creating dealflow and entrepreneur interest.  Life science VC’s are once again behind the curve.  Let’s hope for a change in 2011.

Medical Device Entrepreneur Readings

Illustration of Porters 5 Forces. Illustrates ...
Image via Wikipedia

Over the weekend, a friend asked what one book I would recommend to guide a first-time entrepreneur. I replied that just one book was not sufficient. My friend suggested Michael Porter‘s Competitive Strategy, which I agreed was an excellent choice. I also told him I’d address the question more fully on my blog, so that’s today’s post.

The Launching Tech Ventures Reading List

Fortunately, local entrepreneur and investor Ty Danco recently pointed out an amazing reading list for first time entrepreneurs. Harvard B-School Professor Tom Eisenmann is developing an MBA class called Launching Tech Ventures, and he posted his well-curated course reading list on his blog Platforms and Networks. As Ty says, the list makes me wish I was back in school.   While you’re working through the list, don’t skip Eisenmann’s earlier compendium of the web’s best advice for entrepreneurs.  For tech start-ups, Eisenmann’s recommendations are unsurpassed.

For medical device entrepreneurs, Eisenmann’s list isn’t quite enough, so I’ve put together a few suggestions from my own experience. Leave me a comment telling me what I missed or if you disagree with my choices.

Continue reading “Medical Device Entrepreneur Readings”

Ardian – A Case Study in Value Creation

Image representing Ardian as depicted in Crunc...
Image via CrunchBase

I’m surprised that there hasn’t been more written about Ardian since their sale to Medtronic last month. It may be the largest venture-backed medical device exit to-date. Ardian’s $800M-plus-milestone-payments may end up being larger than Medtronic’s purchase of CoreValve for $700M-plus-milestone-payments in 2009. Even more unusual was Ardian’s relatively early-stage. At the time of sale, CoreValve had implanted devices in 2,600 patients at 125 centers in 25 countries. Ardian exited much earlier, with about 150 patients treated.

Overnight sensations don’t happen overnight. While Ardian seemed to come out of nowhere in 2009 and exited large in 2010, the truth is that the company had been hard at work for almost 10 years. Ardian achieved more than 10X return on $66M invested – at least $732M of value created, before milestones. While the end of the story is still unwritten, Ardian’s first few chapters form a great case study for medical device entrepreneurs and investors.

Continue reading “Ardian – A Case Study in Value Creation”

Stock Options – Wilson’s Rules

Fred Wilson of Union Square Ventures
Image by aquababe via Flickr

One of my most popular posts concerns employee stock options  (see Stock options – everybody in the pool).  Last week, Fred Wilson of Union Square Ventures described his formula for granting employee options, on his blog AVC. Everyone gets options, according to his transparent formula.  Makes a lot of sense to me, and I’m sure it will for you.  Read his post here.

Come Back When You Have More Data

Museum of Bad ArtOver the past several months, I’ve had the privilege of meeting many entrepreneurs who are raising funds for new medical device startups. One common VC refrain they hear: “Come back when you have more data.” Many times this can be a VC’s way of saying no without saying no. Sometimes though, the VC really means what s/he says: the current proof-of-concept data hasn’t proved the concept. It’s not just startups that face this challenge. I’ve seen weak proof-of-concept data in bigger companies too. How can you make sure your proof-of-concept data is solid?

Continue reading “Come Back When You Have More Data”